Organizations in the life sciences, such as pharmaceutical, med tech, and biotech companies, are among the most highly regulated in the global market. Time-to-market (TTM) cycles are correspondingly long due to extensive testing and complex approval processes under FDA and similar guidelines around the globe.
The marketing, payment, and demand processes are also significantly more complex. Between the patient and the producer there is usually an entire series of intermediaries. Doctors prescribe a drug or medical device, pharmacies sell them, and health insurance companies pay the providers. For planning to be both effective and efficient, isolated solutions and siloed data are not an option.
Accurate planning and monitoring of the product portfolio from development to production to distribution plays a central role. Ideally, this is supported by a collaborative planning and analysis approach based on a single source of truth. With a unified, integrated approach to planning, leading life sciences companies can ensure their name brand drugs secure timely research funding before generics take over.
With Jedox and a global network of more than 250 partners, leading organizations in the life sciences streamline their planning. Pharmaceutical, medical device, and biotechnology organizations are increasing collaboration across departments to meet these challenges with a unified, flexible and data-driven approach.